Taysha Gene Therapies (TSHA) Stock Statistics & Valuation Metrics

Taysha Gene Therapies has a market cap or net worth of $638.13M. The enterprise value is $71.38M.

Taysha Gene Therapies has 261,530,400 shares outstanding. The number of shares has decreased by -2.65% in one year.

Taysha Gene Therapies’s return on equity (ROE) is -1.25 and return on invested capital (ROIC) is -67.24%.

The current PE Ratio of Taysha Gene Therapies is -4.85. Taysha Gene Therapies’s PEG ratio is 0.03.

In the last 12 months, Taysha Gene Therapies had revenue of 8.33M and earned -89.30M in profits. Earnings per share was -0.36.

In the last 12 months, operating cash flow was -83.45M and capital expenditures -614.00K, giving a free cash flow of -84.06M billion.

Taysha Gene Therapies pays an annual dividend of ―, resulting in a dividend yield of ―

Taysha Gene Therapies upcoming earnings date is Aug 18, 2025, After Close (Confirmed).

Taysha Gene Therapies as a current ratio of 5.42, with Debt / Equity ratio of 6314.86%

In the past 12 months, Taysha Gene Therapies has paid 0.00 in taxes.

Taysha Gene Therapies EV to EBITDA ratio is -4.06, with an EV/FCF ratio of -4.37.

Taysha Gene Therapies has $116.59M in cash and marketable securities with $61.35M in debt, giving a net cash position of -$55.24M billion.

Gross margin is 0.60%, with operating margin of -1097.55%, and net profit margin of -1071.62%.

The average price target for Taysha Gene Therapies is $8.35, which is 11.43% higher than the current price. The consensus rating is Strong Buy